memantine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wesemann, W | 1 |
| Kryzhanovskii, GN; Kucheryanu, VG | 1 |
| Archer, T; Danysz, W; Fredriksson, A; Quack, G | 1 |
| He, L; Hong, X; Li, J; Wang, X; Zhu, G | 1 |
| Fu, J; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Liu, W; Liu, X; Mizuno, K; Song, S; Wang, C | 1 |
5 other study(ies) available for memantine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Electrochemistry; Free Radicals; Haloperidol; Hydroxyindoleacetic Acid; Male; Memantine; Neurotoxins; Parkinson Disease; Rats; Rats, Wistar; Rotenone; Serotonin; Substantia Nigra | 1992 |
Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Excitatory Amino Acid Antagonists; Glutamic Acid; Ketamine; Male; Memantine; Parkinson Disease, Secondary; Rats; Receptors, N-Methyl-D-Aspartate | 2000 |
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Recovery of Function | 2001 |
MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Calcium Signaling; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Hippocampus; In Vitro Techniques; Male; Memantine; Membrane Glycoproteins; Memory Disorders; Memory, Long-Term; Mice, Inbred C57BL; Neuronal Plasticity; Parkinsonian Disorders; Protein-Tyrosine Kinases; Signal Transduction; Synapses; Time Factors | 2015 |
Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; alpha-Synuclein; Animals; Apoptosis; Cerebral Cortex; Cognitive Dysfunction; Hippocampus; Male; Memantine; Mice, Inbred C57BL; Mitochondria; Mitochondrial Diseases; Morris Water Maze Test; Neurons; Neuroprotective Agents; Open Field Test; Oxidative Stress; Parkinsonian Disorders; Silybin | 2021 |